|
Tegavivint Clinical Trials
4 actively recruiting trials across 4 locations
Also known as: BC 2059, BC-2059, BC2059, Tegatrabetan
Pipeline
Phase 1: 2Phase 1/2: 2
Top Sponsors
- Ohio State University Comprehensive Cancer Center1
- HonorHealth Research Institute1
- Emory University1
- Children's Oncology Group1
Indications
- Cancer4
- Refractory Osteosarcoma2
- Catenin Beta-1 (CTNNB1) Gene Mutation1
- Adenomatous Polyposis Coli (APC) Gene Mutation1
- Liver Disease1
Birmingham, Alabama1 trial
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Hospital of Alabama
Phase 1/2
Scottsdale, Arizona1 trial
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Clinical Trials Nurse Navigator
Phase 1/2
Atlanta, Georgia1 trial
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Arthur M. Blank Children's Healthcare of Atlanta
Phase 1
Columbus, Ohio1 trial
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.